Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CLL/SLL: early-phase trial registry
6 of 7 indexed CLL/SLL trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 6 currently recruiting · #2,497 of 28,707 conditions by registered trial count
CLL/SLL: 7 US clinical trials tracked, 6 recruiting.
CLL/SLL is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Zulfa Omer, running 2 of these trials.
Enrollment posture brief
Registry condition cllsll
OPEN 6 | RECR 86% | LATE 1 | EARLY 6 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenovirus (86% recruiting · 7 trials)
CLL/SLL lists 6 open slots (86% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for CLL/SLL on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
CLL/SLL is recruiting above its size-band peers.
6 of 7 indexed trials (85.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates CLL/SLL research.
Zulfa Omer accounts for 2 of 7 trials (28.6%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most CLL/SLL trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
CLL/SLL research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Global Trial in APG2575 for Patients With CLL/SLL
Ascentage Pharma Group
NCT06104566
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Ascentage Pharma Group
NCT04215809
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
Lomond Therapeutics Holdings
NCT06708897
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical
NCT04775745
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Zulfa Omer
NCT06978088
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Zulfa Omer
NCT07108998
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Synthekine
NCT05665062
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on CLL/SLL records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on CLL/SLL trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this CLL/SLL page
7 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 CLL/SLL trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Zulfa Omer sponsors the most CLL/SLL trials on record, review their full trial history before evaluating a specific study. See Zulfa Omer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CLL/SLL condition card totals 7 registered trials; most-linked intervention LP-168; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.